Ying Teng

804 citations
27 papers · 650 indexed · h-index 12
Topics
Hepatocellular Carcinoma Treatment and Prognosis (5 papers)Cancer-related gene regulation (4 papers)Thyroid Disorders and Treatments (4 papers)
Partner nations
ChinaAustraliaTaiwan

In The Last Decade

Ying Teng

27 papers receiving 637 citations

Peers

Ying Teng
Comparison fields: 5 of 74
  • Molecular Biology 315
  • Oncology 184
  • Hepatology 151
  • Cancer Research 147
  • Pathology and Forensic Medicine 97
Replace Tixiao Wang with:
Tixiao Wang China
Elena Arriazu Spain
Ying Cheng China
Yaqi Zhang China
Weifan Weng United States
Wei Qiu China
Margaret Wilde United States
Konstantina Kyritsi United States
Silke Marhenke Germany
Ying Teng relative to Tixiao Wang China Tixiao Wang's profile →
Citations per field
00.5×7.8×
Tixiao Wang · 1×
Citations per year

Countries citing papers authored by Ying Teng

Since Specialization
Citations

This map shows the geographic impact of Ying Teng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying Teng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying Teng more than expected).

Fields of papers citing papers by Ying Teng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying Teng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying Teng. The network helps show where Ying Teng may publish in the future.

Co-authorship network of co-authors of Ying Teng

This figure shows the co-authorship network connecting the top 25 collaborators of Ying Teng. A scholar is included among the top collaborators of Ying Teng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying Teng. Ying Teng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 11
2 11
3 100
4 5
5 1
6 12
7 41
8 11
9 12
10 3
11 11
12 8
13 8
14 37
15 9
16 215
17
[Effect of siRNA-mediated beta-catenin gene on Wnt signal pathway in lung adenocarcinoma A549 cell].
4
18 12
19 4
20 28

About Ying Teng

Ying Teng is a scholar working on Hepatology, Pathology and Forensic Medicine and Endocrinology, Diabetes and Metabolism, having authored 27 papers that have together received 650 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Cancer-related gene regulation (4 papers) and Thyroid Disorders and Treatments (4 papers). The work is most often cited by research in Hepatology (151 citations), Cancer Research (147 citations) and Oncology (184 citations). Ying Teng has collaborated with scholars based in China, Australia and Taiwan. Frequent co-authors include Xiuwen Wang, Yawei Wang, Daoxin Ma, Xiaoyan Ding, Wei Sun, Wendong Li, Jinglong Chen, Yanjun Shen, Wei Li and Xiaodi Guo. Their work appears in journals such as Cancer, Biochemical and Biophysical Research Communications and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026